QuidelThe FDA issued an emergency use authorization today for the Quidel Corp. (NSDW:QDEL) QuickVue At-Home COVID-19 test, another antigen test to rapidly collect and test samples at home, without needing to send a sample to a laboratory for analysis.

The QuickVue At-Home COVID-19 test is authorized for prescription home use with self-collected anterior nasal swabs from people ages 14 and older or children ages 8 and older with swabs collected by an adult. The test is authorized for those suspected of COVID-19 by their healthcare provider within the first six days of symptom onset.

“The FDA continues to prioritize the availability of more at-home testing options in response to the pandemic,” said Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health, said in a news release. “The QuickVue At-Home COVID-19 test is another example of the FDA working with test developers to bring important diagnostics to the public.”

In February, Quidel opened a new factory in Carlsbad, Calif., for its QuickVue line of products. The 128,000 square-foot facility will be the company’s highest-volume production plant in the world and begins operations in the second half of 2021 with a mission to produce 600 million QuickVue SARS rapid antigen tests per year for the detection and diagnosis of COVID-19 infections. That test received an EUA from the FDA in December.

In December, the FDA granted an EUA to Abbott (NYSE: ABT) for virtually-guided, at-home use of the company’s BinaxNow COVID-19 Ag Card and to Ellume for its Ellume COVID-19 Home test — the first fully at-home test for the novel coronavirus that the agency is authorizing for over-the-counter sales.